Who makes Medium dose HB-101?

Medium dose HB-101 is developed by Hookipa Biotech GmbH.

What development phase is Medium dose HB-101 in?

Medium dose HB-101 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

Medium dose HB-101

Hookipa Biotech GmbH · Phase 1 active Biologic Quality 0/100

At a glance

Generic name	Medium dose HB-101
Sponsor	Hookipa Biotech GmbH
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Medium dose HB-101 CI brief — competitive landscape report
Medium dose HB-101 updates RSS · CI watch RSS
Hookipa Biotech GmbH portfolio CI